Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs 2,637

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 34 of 55

  1. MS201924_0022

    Merck Sharp and Dohme

    Non-Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. MT-401

    Marker Therapeutics

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  3. MaaT033 capsule

    Regeneron UK Limited

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  4. Mektovi film-coated tablets for metastatic colorectal cancer wi…

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  5. Metformin Hydrochloride ER

    Atrium Therapeutics

    Sarcoma Metastatic

    phase 2 small molecule active

    1 trial

  6. Methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  7. Methotrexate tablets

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Midostaurin

    Novartis Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  9. Mifamurtide

    Takeda

    Osteosarcoma

    phase 2 small molecule terminated

    1 trial

  10. Mifepristone

    CORCEPT THERAPEUTICS INC

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  11. Mitomycin C

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  12. Mitomycin C

    HALOZYME THERAPEUTICS, INC.

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  13. Mitoxantrone Hydrochloride Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. Mitoxantrone liposome

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  15. MoLuoDan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Precancerous Condition

    phase 2 small molecule active

    1 trial

  16. Modakafusp Alfa

    Teva Generics B.V

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  17. Modakafusp Alfa

    Teva Pharma GmbH

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  18. Monalizumab

    MedImmune

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  19. Mosunetuzumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  20. Mosunetuzumab

    Adaptive Biotechnologies Corp

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  21. Motixafortide

    Regeneron UK Limited

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  22. Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  23. Multi-epitope HER2 Peptide Vaccine TPIV100

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 2 mab active

    1 trial

  24. Myocet (Non-pegylated liposomal doxorubicin (NPLD))

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  25. NALIRIFOX+Adebrelimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  26. NAP (Naptumomab estafenatox)

    BRIGHT MINDS BIOSCIENCES INC.

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  27. NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

    RELMADA THERAPEUTICS, INC.

    Non Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  28. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  29. NEO-TIM

    Fondazione Telethon ETS

    high-risk, surgically resectable BRAF mutated and wild-type Melanoma

    phase 2 small molecule active

    1 trial

  30. NERATINIB

    PUMA BIOTECHNOLOGY, INC.

    Stage IV (Metastatic) Breast Cancer

    phase 2 small molecule terminated

    1 trial

  31. NERATINIB, Sindiar 2 mg cápsulas duras

    Ningbo Cancer Hospital

    HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.

    phase 2 small molecule active

    1 trial

  32. NIVOLUMAB, TEDOPI

    Fondazione Telethon ETS

    metastatic non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  33. NJMU-BC01

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  34. NK cell and PD-1 antibody

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  35. NK cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  36. NK cells

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  37. NKTR-102

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  38. NKTR-102

    Nektar Therapeutics UK Limited

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  39. NKTR-102 100 mg/m2

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  40. NKTR-102 145 mg/m2

    Nektar Therapeutics UK Limited

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

  41. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  42. NKTR-214

    Nektar Therapeutics UK Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  43. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  44. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  45. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

  46. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  47. NKTR-262

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule terminated

    1 trial

  48. NOV-002

    Cellectar Biosciences

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,637 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.